Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Cancer Research and Clinical Oncology
Published in: Journal of Cancer Research and Clinical Oncology 11/1998

01-11-1998 | ORIGINAL PAPER

Stability and cellular studies of [rac-1,2-bis(4-fluorophenyl)- ethylenediamine][cyclobutane-1,1-dicarboxylato]platinum(II), a novel, highly active carboplatin derivative

Authors: Ronald Gust, Beate Schnurr, Rudolf Krauser, Günther Bernhardt, Marion Koch, Beate Schmid, Evelyn Hummel, Helmut Schönenberger

Published in: Journal of Cancer Research and Clinical Oncology | Issue 11/1998

Login to get access
Metadata
Title
Stability and cellular studies of [rac-1,2-bis(4-fluorophenyl)- ethylenediamine][cyclobutane-1,1-dicarboxylato]platinum(II), a novel, highly active carboplatin derivative
Authors
Ronald Gust
Beate Schnurr
Rudolf Krauser
Günther Bernhardt
Marion Koch
Beate Schmid
Evelyn Hummel
Helmut Schönenberger
Publication date
01-11-1998
Publisher
Springer-Verlag
Published in
Journal of Cancer Research and Clinical Oncology / Issue 11/1998
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI
https://doi.org/10.1007/s004320050220

Other articles of this Issue 11/1998

Journal of Cancer Research and Clinical Oncology 11/1998 Go to the issue

ORIGINAL PAPER

Changes of immunological markers after autologous peripheral blood stem cell transplantation

ORIGINAL PAPER

Inhibition of tumour cell invasion by protease inhibitors: correlation with the protease profile

ORIGINAL PAPER

Emergence of higher levels of invasive and metastatic properties in the drug resistant cancer cell lines after the repeated administration of cisplatin in tumor-bearing mice

ORIGINAL PAPER

Restoration of the p16 gene is related to increased radiosensitivity of p16-deficient lung adenocarcinoma cell lines

OriginalPaper

Erratum: J Cancer Res Clin Oncol (1998) 124: 367–373

ORIGINAL PAPER

Bendamustine as salvage treatment in patients with advanced progressive breast cancer: a phase II study
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits